| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | ||||||
|
30.04.2025 17:54:39
|
EQS-Adhoc: BRAIN Biotech AG reports preliminary Q2 figures and forecasts a more conservative development for the second half of the fiscal year 2024/25
|
EQS-Ad-hoc: BRAIN Biotech AG / Key word(s): Preliminary Results/Change in Forecast BRAIN Biotech AG reports preliminary Q2 figures and forecasts a more conservative development for the second half of the fiscal year 2024/25 Zwingenberg, Germany, 30 April 2024 – BRAIN Biotech AG (ISIN DE0005203947; “BRAIN” or “Company”) today reports preliminary Q2 figures for the financial year 2024/25 with Q2 revenues of EUR 12.12 million and an adjusted EBITDA of minus EUR 0.36 million. The publication of the comprehensive half year reporting for 31 March 2025 (6M) and the analyst call will take place as previously scheduled on May 28th, 2025. Due to the overall weaker economic environment and strong USD currency fluctuations the Company now forecasts full-year 2024/25 revenues for the core segment BRAINBiocatalysts to be around the level of last year and therefore below the original guidance. The guidance for the adjusted EBITDA margin in the segment BRAINBiocatalysts and the guidance for the segment BRAINBioIncubator remains unchanged.
Notifying person: Martina Schuster www.brain-biotech-group.com Investor Relations Office
End of Inside Information
30-Apr-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | BRAIN Biotech AG |
| Darmstädter Straße 34-36 | |
| 64673 Zwingenberg | |
| Germany | |
| Phone: | +49 (0) 62 51 / 9331-0 |
| Fax: | +49 (0) 62 51 / 9331-11 |
| E-mail: | ir@brain-biotech.com |
| Internet: | www.brain-biotech.com |
| ISIN: | DE0005203947 |
| WKN: | 520394 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2128270 |
| End of Announcement | EQS News Service |
|
|
2128270 30-Apr-2025 CET/CEST
Nachrichten zu BRAIN Biotech AG
3 Knaller-Aktien im BX Musterportfolio📈: Thales, Generali & Swiss Life mit François Bloch
Im BX Morningcall werden folgende Aktien analysiert und erklärt:
📌 Thales Group (FR0000121329)
📌 Assicurazioni Generali (IT0000062072)
📌 Swiss Life Holding (CH0014852781)
➡️ Ausserdem zeigen wir, welche Aktien das Portfolio verlassen haben und warum:
❌ Meta Platforms (US30303M1027)
❌ LPL Financial (US50212V1008)
❌ American Express (US0258161092)
Pünktlich zum Börsenstart diskutieren Investment-Stratege François Bloch und Börsen-Experte David Kunz oder Olivia Hähnel über ausgewählte Top-Aktienwerte aus dem BX Musterportfolio.
👉🏽 https://bxplus.ch/bx-musterportfolio/
Inside Trading & Investment
Mini-Futures auf SMI
Aktien in diesem Artikel
| BRAIN Biotech AG | 3.97 | 87.21% |
|
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
SMI startet kaum verändert -- DAX startet in Grün - Rekordmarke im Visier -- Asiens Börsen in GrünDer heimische Aktienmarkt verändert sich zum Start der Sitzung kaum, während der deutsche Aktienmarkt etwas zulegt. An den Aktienmärkten in Fernost findet ein freundlicher Handel statt.
finanzen.net News
| Datum | Titel |
|---|---|
|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |